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Abstract
Background: The flat bones of the skull (i.e., the frontal and parietal bones) normally form
through intramembranous ossification. At these sites cranial mesenchymal cells directly
differentiate into osteoblasts without the formation of a cartilage intermediate. This type of
ossification is distinct from endochondral ossification, a process that involves initial formation of
cartilage and later replacement by bone.
Results: We have analyzed a line of transgenic mice that expresses FGF9, a member of the
fibroblast growth factor family (FGF), in cranial mesenchymal cells. The parietal bones in these mice
show a switch from intramembranous to endochondral ossification. Cranial cartilage precursors
are induced to proliferate, then hypertrophy and are later replaced by bone. These changes are
accompanied by upregulation of Sox9,  Ihh,  Col2a1,  Col10a1  and downregulation of CbfaI  and
Osteocalcin. Fate mapping studies show that the cranial mesenchymal cells in the parietal region that
show a switch in cell fate are likely to be derived from the mesoderm.
Conclusion:  These results demonstrate that FGF9 expression is sufficient to convert the
differentiation program of (at least a subset of) mesoderm-derived cranial mesenchyme cells from
intramembranous to endochondral ossification.
Background
Bone development can occur in two distinct ways: 1)
through endochondral ossification where the mesenchy-
mal cells differentiate into chondrocytes and lay down a
cartilaginous template that is later replaced by bone; or 2)
through intramembranous ossification where mesenchy-
mal cells directly differentiate into osteoblasts without the
formation of a cartilage intermediate. During endochon-
dral ossification, the transcription factors Sox9, Sox5 and/
or Sox6 are expressed and are involved in the induction of
chondrocytes [1]. Chondrocytes in the growth plate are
subsequently induced to exit the cell cycle and commit to
terminal differentiation. The prehypertrophic chondro-
cytes mature into hypertrophic chondrocytes, which lay
down a matrix rich in Collagen X, and secrete VEGF [2].
VEGF promotes the invasion of blood vessels from the
perichondrium, bringing in both the bone forming oste-
oblasts and the bone resorbing osteoclasts. The hyper-
trophic chondrocytes then undergo apoptosis, and are
replaced by trabecular bone and bone marrow. In con-
trast, the flat bones of the skull, the frontal and parietal
bones, form by intramembranous ossification. Cranial
mesenchymal cells directly differentiate into osteoblasts
that initiate mineralization and secrete an extracellular
matrix rich in Collagen I [3]. Growth of these calvarial
bones occurs through proliferation and differentiation of
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osteoblasts at the margins or sutures. The molecular path-
ways that dictate these alternative ossification programs
are not yet well defined. In particular, it is not known
whether intramembranous ossification is prespecified by
the ontogeny of the cranial mesenchyme or is a response
to local environmental signals.
Fibroblast growth factors (FGFs) appear to be important
for both types of ossification [4]. FGFs comprise a large
family of proteins that includes at least 22 known mem-
bers [5]. FGFs bind and signal through low and high affin-
ity FGF receptors [5]. The four known high affinity
receptors (FGFR1–4) are structurally similar transmem-
brane receptor tyrosine kinases. During intramembranous
ossification of the flat bones, FGFR1–3 are expressed by
the differentiating osteoblasts at the osteogenic fronts and
also by the adjacent cartilage [6,7]. FGFR1 is expressed in
cells close to and within the osteoid; FGFR2 is expressed
Abnormal head development in the OVE1070 FGF9 transgenic mice Figure 1
Abnormal head development in the OVE1070 FGF9 transgenic mice. Panel A shows a schematic representation of the FGF9 
transgene. The coding region of mouse Fgf9 cDNA was inserted between the αA-crystallin promoter (αAp) and an intron and 
polyadenylation sequence derived from SV40 virus [47]. The microinjection fragment was generated by SstII digestion. The 
SV40 sequences were used to make a riboprobe for detection of expression of the transgene. (B and C) Three day old non-
transgenic (NT) and FGF9 transgenic mice are shown. The heads of the transgenic mice are 'dome' shaped (C). The OVE1070 
transgenic mice often show unfused eyelids at birth (C). (D-K) Skeletal preparations of the FGF9 transgenic mice reveal an 
expansion in the cartilage territory in the head region. Alcian blue and Alizarin red stained E15 (D and E), P3 (F and G), P10 (H 
and I) and P30 (J and K) heads are shown. Cartilage is stained blue and bone red. The insets in panels D and E are higher mag-
nifications of the frontal and parietal bones in the nontransgenic and transgenic mice respectively. The insets in panels F-I are 
rear views. The insets in panels J and K are top views. An expansion in the cartilage territory is seen in the FGF9 transgenic 
mice. Parietal bone (p) is affected in the transgenic skulls but the coronal suture is still present (E inset, arrow). Frontal (f) and 
occipital bone formation appear to be unaffected (E and G insets). A hole forms in the skull of the FGF9 transgenic mice that is 
visible by P3 (G inset, arrow) and is seen to persist at P10 (I inset, arrow). The red stain visible at the arrow in the inset in 
panel G is bone at the base of the head, which is visible since the skull and the brain are transparent after staining and clearing. 
The cartilage territory is replaced by bone by P30 (K and inset). Scale bar: 1 mm in D and E; 1.6 mm in F and G; 2.5 mm in H-K.BMC Developmental Biology 2006, 6:7 http://www.biomedcentral.com/1471-213X/6/7
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in the proliferating osteogenic stem cells; FGFR3 expres-
sion is seen in the thin layer of cartilage underlying the
lower part of the coronal suture [6]. As FGFR3 null mice
do not show defects in calvarial development, it has been
hypothesized that intramembranous bone formation is
controlled primarily by FGFR1 and FGFR2 [8]. Mutations
in FGFR1, FGFR2 and FGFR3 in humans that affect skele-
tal growth are consistent with this hypothesis [9]. Cranio-
synostosis is mainly associated with mutations in FGFR1
and FGFR2 [9]. Mutations that affect the growth of long
bones resulting in syndromes such as Achondroplasia
(Ach) and Thanatophoric dysplasia (TD) are mainly local-
ized to FGFR3. These autosomal dominant disorders are
believed to reflect either an enhancement of receptor
activity or a neomorphic gain-of-function effect [9-11].
During long bone development, FGF receptors are
expressed in the epiphyseal growth plates: FGFR3 is
expressed in the proliferating chondrocytes; FGFR1 is
expressed in the hypertrophic chondrocytes; FGFR1 and
FGFR2 are expressed in the perichondrium [4,12]. FGFR2
is expressed in early mesenchymal condensates and in the
periosteal collar around the cartilage models [8]. Targeted
deletion of FGFR2IIIc suggests that FGFR2IIIc is a positive
regulator of ossification in both the osteoblasts and
chondrocytic lineages [13]. Targeted deletion of FGFR3
results in mice that show overgrowth of the long bones
and abnormal proliferation of chondrocytes suggesting
that FGFR3 stimulation inhibits chondrocyte prolifera-
tion [14]. These studies describe roles for FGF receptor-
mediated signaling during differentiation/maturation of
chondrocytes.
The roles of FGF ligands in skeletal development are
unclear. During calvarial development, Fgf8 is expressed
in the osteoblasts; Fgf2  and  Fgf4  are expressed in the
sutural mesenchyme; Fgf18 is initially expressed in the
cranial mesenchymal cells and later, in the differentiating
osteoblasts [8]. Fgf9 is expressed in the sutural mesen-
chyme and is upregulated in the endocranial portions of
the mesenchyme and is downregulated during postnatal
development [15][16]. The specific in vivo functions of
these different FGFs remain undefined. In vitro, cephalic
neural crest cells from quail embryos have been shown to
respond to exogenous FGF-2 in a dose dependant man-
ner; lower doses induce proliferation and higher doses
induce cartilage differentiation [17]. During long bone
development, at the time of initiation of endochondral
differentiation, Fgf9 is expressed in the condensing mes-
enchyme [18]. Fgf2, Fgf5, Fgf6 and Fgf7 are expressed in
loose mesenchyme outside the condensation [19-23].
However, mice lacking these Fgfs show no apparent
defects in skeletal development [24-28]. Functional
redundancy between these FGFs may, in part, account for
the lack of phenotype. Therefore, roles for these Fgfs in the
early stages of chondrogenesis have not yet been defined.
In this study, we have analyzed transgenic mice that
express FGF9 in their cranial mesenchymal cells. These
mice show abnormal head development and are born
with a pronounced bulge in their skulls. Skeletal prepara-
tions of these mice revealed dramatic changes in parietal
bone formation. In the region where the parietal bones
normally form, cranial mesenchymal cells are induced to
differentiate into chondrocytes that proliferate, hypertro-
phy and subsequently differentiate as bone. Correlative
changes in expression of marker genes Sox9,  Col2a1,
Col10a1, Ihh, CbfaI and Osteocalcin occur in conjunction
with the altered differentiation program. Thus the parietal
bones in these mice form by endochondral ossification
rather than by the usual intramembranous ossification
route. Fate mapping studies indicate that the ectopic carti-
lagenous precursors in these mice are derived from the
mesoderm. Based on these results we suggest that cranial
mesenchymal cells are competent to initiate endochon-
dral ossification, and can be switched to this alternative
developmental program by ectopic expression, or overex-
pression, of FGF9.
Results
Changes in cranial morphology in the FGF9 transgenic 
mice
Transgenic mice were generated by microinjection of a
construct with the αA-crystallin promoter linked to a
mouse Fgf9 cDNA (Fig. 1A) [29]. Eleven founders carrying
the transgene were identified. Five of them had cataracts
(data not shown). In the transgenic line OVE1070, in
addition to lens defects, there were defects in the develop-
ment of the skull (Fig. 1B, C). Mice in this family that are
heterozygous for the transgene are born with 'dome-
shaped' heads (Fig. 1C). This phenotype is even more pro-
nounced in homozygous transgenic mice (data not
shown).
Calvarial development in FGF9 transgenic mice
The skeletal defects were examined by Alcian blue and Ali-
zarin red staining of E15, P3, P10 and P30 mice (Fig. 1D–
K). The skeletal preparations show a dramatic expansion
of cartilage in the head region by E15 (compare Fig. 1E to
1D). Parietal bone development was particularly affected
(Fig. 1E and inset). At P3, the phenotypic differences
between the nontransgenic and FGF9 transgenic mice
were still pronounced. At this age, the calvarial skull in
nontransgenic mice is mostly ossified except at the sutures
(Fig. 1F). In contrast, there is an expanded cartilage terri-
tory (blue) in the FGF9 transgenic mice (Fig. 1G). The
transgenic mice also show a central hole in the skull where
there is neither cartilage nor bone (Fig. 1G, inset, arrow).
Development of the occipital bones appeared normal
(Fig. 1G and inset). At P10, the Alcian blue stained tissues
in the transgenic cranium were interspersed with Alizarin
red stained regions suggesting that the cartilage territoryBMC Developmental Biology 2006, 6:7 http://www.biomedcentral.com/1471-213X/6/7
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was being replaced by bony structures (Fig. 1I). By 1
month of age, the cartilage territory was completely
replaced by bone (Fig. 1K and inset).
The alterations in skeletal development in the FGF9 trans-
genic mice were examined at the histological level by anal-
yses of hematoxylin and eosin stained sections of the
cranium. No distinctive differences in morphology were
seen at E11 (data not shown). By E13, more cranial mes-
enchymal cells were seen in the skull region of the FGF9
transgenic mice (Fig. 2B, B') and these cells were organ-
ized differently from nontransgenic mice (compare Fig.
2A, B). By E15, the cranial mesenchymal cells in the non-
transgenic mice had initiated intramembranous ossifica-
tion (Fig. 2C, C', arrow). In contrast, the mesenchymal
cells in the FGF9 transgenic skulls differentiated into cells
resembling chondrocytes (Fig. 2D, D'). Within the next
few days these cells increased in size and became hyper-
trophic (Fig. 2F, F', H, H'). By P7, perichondrial cells
(including the blood vessels) had begun to invade the car-
tilage territory (Fig. 2J, J'). By P18, the cartilage territory
was transformed into trabecular bone and bone marrow
(Fig. 2L, L'). These results considered together suggest that
the cranial mesenchymal cells in the parietal region in
these mice recapitulate the sequence of events that occurs
during endochondral ossification.
Ectopic expression of the FGF9 transgene
To test if the alterations seen in the skulls of the OVE1070
mice were due to ectopic expression of the transgene, in
situ hybridizations were performed using an S35-labelled
riboprobe that recognizes the SV40 portion of the trans-
gene (Fig. 1A). Transgene expression was seen in the lens
[29], the dorsal portion of the retinal pigmented epithe-
Cranial mesenchyme in the FGF9 transgenic mice differentiates into chondrocytes Figure 2
Cranial mesenchyme in the FGF9 transgenic mice differentiates into chondrocytes. Heads of nontransgenic (A, A', C, C', E, E', 
G, G', I, I', K and K') and FGF9 transgenic mice (B, B', D, D', F, F', H, H', J, J', L and L') were sectioned and stained with hema-
toxylin and eosin. Panels A'-L' are higher magnifications of the boxed regions in panels A-L respectively. In nontransgenic mice, 
the mesenchymal cells of the skull form a skeletogenic membrane (arrows in A', C', E' and G') within which the bones form. In 
the FGF9 transgenic mice the cranial mesenchymal cells (cm) differentiate into chondrocytes (ch) that initially form a structure 
resembling the hyaline cartilage (D, D', F and F') and later hypertrophy (hyp) (H, H', J and J'). Perichondrial cells, including blood 
cells (J', arrows) invade and replace the hypertophic chondrocytes forming bone and bone marrow (L and L'). Other abbrevia-
tions: b, brain; s, skin. The folding seen in the section in panel G is an artifact of the histology procedure. Note that the skin was 
removed from P7 and P18 mice to facilitate fixation and histological processing. Scale bar: 50 µm in A'-L'; 100 µm in A, B, C, D, 
E, H, I and K; 200 µm in F, G, J and L.BMC Developmental Biology 2006, 6:7 http://www.biomedcentral.com/1471-213X/6/7
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lium [30] and also in the cranial mesenchymal cells begin-
ning at E11 (Fig. 3B', D', F'). Expression levels peak by E13
and start to decrease by E15 (Fig. 3D', F'). Transgene
expression is extinguished by E17 (data not shown). Sec-
tion and whole mount in situ hybridizations show that
the extraocular transgene expression is restricted to the
mesenchymal cells overlying the future mid and hind
brain regions (Fig. 3G, arrows; 3H-M). These results argue
that the defects in skeletal development in the OVE1070
line are attributable to ectopic and transient expression of
the FGF9 transgene.
Expression of chondrocyte specific markers
The different stages of endochondral ossification are char-
acterized by expression of different marker genes. Expres-
sion of Sox9, a member of the Sox family of transcription
factors, has been shown to be essential for chondrocyte
condensation [31]. In particular, Sox9 is required for the
expression of cartilage-specific extracellular matrix com-
ponents such as Collagen II (Col2a1) [32]. In the long
bone growth plates, Col2a1 is expressed in the resting and
proliferating chondrocytes, Ihh  in prehypertropic
chondrocytes and Col10a1 in hypertropic chondrocytes
Expression pattern of the transgene Figure 3
Expression pattern of the transgene. In situ hybridizations were done on sections of heads from nontransgenic (NT) and FGF9 
transgenic mice using a [35S]-labeled SV40 riboprobe. Panels A-F show bright-field images and panels A'-F' show the corre-
sponding dark field images. Transgene expression can be seen in the cranial mesenchymal cells at E11 (B'), E13 (D') and E15 
(F'). At later stages, expression of the transgene in the cranium was not detected (data not shown). Transgene expression was 
restricted to the mesenchymal cells overlying the mid (m) to hind brain regions (h) but not the forebrain (f) (G, arrows). Scale 
bar: 100 µm in A-F'. Whole mount in situ hybridizations on E12.5 heads using a digoxygenin-labelled SV40 riboprobe show 
expression of the transgene (purple color) in the cranial regions (H-K). Panels H and I are rear views and panels J and K are top 
views. Scale bar: 1 mm in H, I and K.BMC Developmental Biology 2006, 6:7 http://www.biomedcentral.com/1471-213X/6/7
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[3]. Expression of the runt domain transcription factor
CbfaI has been shown to be essential for differentiation of
the cells in the osteoblastic lineage [33]. Osteocalcin, one
of the downstream targets of CbfaI, is expressed exclu-
sively in the osteoblasts [34]. Expression of these six
marker genes was examined by in situ hybridization using
Expression patterns of Sox9, CbfaI and Osteocalcin Figure 4
Expression patterns of Sox9, CbfaI and Osteocalcin. In situ hybridizations were done on sections of heads from nontransgenic 
(NT) and FGF9 transgenic mice using [35S]-labeled riboprobes for Sox9 (A-F'), CbfaI (G-H') and osteocalcin (I-J'). Panels A-J are 
bright field images and panels A'-J' are the corresponding dark-field images. Expression of Sox9 is induced in the cranial mesen-
chymal cells of the FGF9 transgenic mice by E13 (D'). Sox9 expression is detected in the ventricular regions of the brain at E13 
in both the transgenic and nontransgenic mice (C', D'). CbfaI and osteocalcin are expressed in the differentiating calvarial oste-
oblasts (os) of nontransgenic mice at E15 (G', I') but not in the skulls of the FGF9 transgenic mice (H', J'). Scale bar: 50 µm in G-
J'; 100 µm in A-F'.BMC Developmental Biology 2006, 6:7 http://www.biomedcentral.com/1471-213X/6/7
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Expression patterns of Col2a1, Col10a1 and Ihh Figure 5
Expression patterns of Col2a1, Col10a1 and Ihh. In situ hybridizations were done on sections of heads from nontransgenic (NT) 
and FGF9 transgenic mice using [35S]-labeled riboprobes for Col2a (A-H'), Col10a1 (I-J') and Ihh (K-L'). Panels A-L are bright 
field images and panels A'-L' are the corresponding dark-field images. Expression of Col2a1 is enhanced in the cranial mesenchy-
mal cells of the FGF9 transgenic mice by E15 (B') and is decreased in some cells by P7 (H'). Hybridizations performed on adja-
cent sections show expression of Col10a1 in these hypertropic (hyp) chondrocytes (J'). Ihh expression was detected in the 
differentiated chondrocytes by P7 (L'). Abbreviations: b, brain; ch, chondrocytes; hyp, hypertropic chondrocytes; os, osteob-
lasts; s, skin. Scale bar: 100 µm in A-L'.BMC Developmental Biology 2006, 6:7 http://www.biomedcentral.com/1471-213X/6/7
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Expression patterns of Fgf9, Fgfr2 and Fgfr3 Figure 6
Expression patterns of Fgf9, Fgfr2 and Fgfr3. In situ hybridizations were done on sections of heads from nontransgenic (NT) and 
FGF9 transgenic mice using [35S]-labeled riboprobes for Fgf9 (A-D'), Fgfr2 (E-H') and Fgfr3 (I-L'). Panels A-L are bright field 
images and panels A'-L' are the corresponding dark-field images. Expression of Fgf9 is not seen in the cranial mesenchymal (cm) 
cells of the nontransgenic mice at E11 (A') or E13 (C') in contrast to age-matched sections of FGF9 transgenic heads (B' and 
D'). Modest Fgfr2 expression is detected in the cranial mesenchymal cells at E11 in both the transgenic and nontransgenic mice 
(E' and F') and persists in the expanded cranial mesenchyme at E13 (H'). Fgfr3 expression is initially not seen in the cranial mes-
enchymal (cm) cells at E11 (J') but low level expression can be detected in the transgenic mesenchyme at E13 (L'). Scale bar: 
100 µm in A-L'.BMC Developmental Biology 2006, 6:7 http://www.biomedcentral.com/1471-213X/6/7
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S35-labelled riboprobes (Figs. 4 and 5). No appreciable
differences in expression of Sox9 between nontransgenic
and FGF9 transgenic mice were seen at E11 (Fig. 4A, A', B,
B'). However, significant induction of Sox9 expression was
seen in the cranial mesenchymal cells of the transgenic
mice by E13 (Fig. 4C, C', D and 4D'). Sox9 expression was
seen to persist in the developing chondrocytes (Fig. 4F,
F'). CbfaI and Osteocalcin are expressed during the normal
program of intramembranous ossification in nontrans-
genic mice, but their expression was not seen in the corre-
sponding regions of the embryonic transgenic heads (Fig.
4G–J').
Col2a1 expression was seen in the developing chondro-
cytes in the transgenic cranium but not the wildtype, at
E15, E17 and P3 (Fig. 5A–F'). By P3 expression levels were
found to be reduced in transgenic hypertropic chondro-
cytes (Fig. 5E–H'). In situ hybridizations at P7 showed
that  Col10a1  and  Ihh  are expressed in the hypertropic
chondrocytes (Fig. 5I–L'). Expression of Col10a1 was not
seen in the chondrocytes at P3 or before (data not
shown). These results demonstrate that the transgenic cra-
nial mesenchymal cells undergo endochondral ossifica-
tion instead of intramembranous ossification.
Expression of Fgf9, Fgfr2 and Fgfr3
Fgf9 has been reported to be expressed in cranial mesen-
chymal cells as well as in the dural mesoderm during
embryonic development [16]. Expression levels of the
Fgf9 transgene and endogenous Fgf9 were compared by in
situ hybridizations using an [35S]-labelled Fgf9 riboprobe
(Fig. 6A–D'). At E11 and E13, Fgf9 was not expressed at
detectable levels in the cranial mesenchymal cells in non-
transgenic mice. In contrast, Fgf9 expression was clearly
present in the transgenic mice (Fig. 6A–D').
As FGF9 binds to and signals through FGFR2 and FGFR3,
in situ hybridizations were performed to examine their
expression levels (Fig. 6E-L'). Low levels of Fgfr2 expres-
sion can be seen in cranial mesenchymal cells at E11 in
both the nontransgenic and transgenic mice (Fig. 6E, E', F
and 6F'). Fgfr2 expression is maintained in the induced
chondrocytes in the transgenic mice (Fig. 6H, H'). In con-
trast, Fgfr3 expression was not detected at E11 either in
transgenic or in nontransgenic cranial mesenchyme (Fig.
6I, I', J, J'). Fgfr3 was expressed at low levels in the differ-
entiating chondrocytes of the FGF9 transgenic mice (Fig.
6L, L'). In addition, crossing the OVE1070 mice with
FGFR3 null mice [14] does not alter the "dome-head"
phenotype (data not shown). These results taken together
suggest that the developmental switch in the transgenic
mice may initially be mediated by ectopic activation of
FGFR2.
FGF9 induces proliferation of the cranial mesenchymal 
cells
To test if the cranial mesenchymal cells proliferate in
response to FGF9 expression, sections of E11 and E13
BrdU incorporation and cell proliferation Figure 7
BrdU incorporation and cell proliferation. BrdU incorporation (brown stain) was detected by immunohistochemistry (A-D). A 
significant increase in BrdU positive (brown stained nuclei) cells was detected in the parietal region of the FGF9 transgenic 
mice at E11 and at E13 (E). Scale bar: 100 µm in A-D.BMC Developmental Biology 2006, 6:7 http://www.biomedcentral.com/1471-213X/6/7
Page 10 of 14
(page number not for citation purposes)
skulls were assayed for BrdU incorporation (Fig. 7). At
E11 and at 13, the cranial mesenchymal cells in the pari-
etal region of FGF9 transgenic mice show a significant
increase in BrdU incorporation (Fig. 7A–D). These results
suggest that FGF9 expression in the cranial mesenchymal
cells results in increased proliferation.
Fate mapping of cells in the parietal region in the FGF9 
transgenic mice
Cell lineage tracing studies performed in mice and in
chicks show that the cranial skeletogenic mesenchyme is
derived from two sources, neural crest and mesoderm [35-
37]. To determine if the cells in the parietal region that
form ectopic cartilage in the OVE1070 mice are neural
crest or mesodermal derivatives, we performed fate map-
ping experiments using Wnt1-Cre and R26R mice [38,39].
As has been described previously, Wnt1-Cre/R26R com-
pound heterozygotes stably express β-galactosidase in
neural crest cells and their descendants but not in the mes-
odermal derivatives [40,41]. OVE1070 mice were crossed
with Wnt1-Cre/R26R mice and heads of E17 embryos
were stained with X-Gal (Fig. 8). In the absence of Wnt1-
Cre,  lacZ  positive cells were not detected in the R26R
embryo (A, A') or in the FGF9/R26R embryo (B, B'). In the
Wnt1-Cre/R26R embryo (C,C'), the parietal region (p) of
the skull showed no evidence for lacZ activity, implying
that neural crest derivatives do not contribute to this
region of the skull. In the FGF9/Wnt1-Cre/R26R embryo
(D, D'), there is also no blue staining in the (enlarged)
parietal region. These results establish that the cells in the
parietal region that form ectopic cartilage in the OVE1070
mice are not neural crest derived but are for the most part,
derived from mesoderm. In summary, in family
OVE1070, ectopic FGF9 expression switches the differen-
tiation and proliferation properties of cranial mesodermal
cells, resulting in inhibition of intramembranous ossifica-
tion and conversion to a program of endochondral ossifi-
cation.
Discussion
In this study, we have analyzed a line of transgenic mice
where the differentiation program of a portion of the cra-
nial mesenchyme is converted from intramembranous to
endochondral ossification. The transgenic mice ectopi-
cally express FGF9 in their cranial mesenchymal cells.
Expression of FGF9 correlates with localized proliferation
of the mesenchymal cells and with upregulation of Sox9
expression and downregulation of CbfaI and Osteocalcin.
The mesenchymal cells consequently differentiate into
chondrocytes that express Col2a1. These chondrocytes
proliferate, then hypertrophy, express Col10a1and are
later replaced by trabecular bone and bone marrow.
Therefore, parietal bone formation in these mice recapitu-
lates the sequence of events that occurs during endochon-
dral ossification. These results demonstrate that FGF9
expression is sufficient to convert the differentiation pro-
Fate mapping studies in the OVE1070 cranium Figure 8
Fate mapping studies in the OVE1070 cranium. X-Gal staining of E17 embryos. Panels A-D are top views and panels A'-D' are 
lateral views of intact heads. In the absence of Wnt1-Cre, lacZ positive cells were not detected in the R26R embryo (A, A') or 
the FGF9/R26R embryo (B, B'). In the Wnt1-Cre/R26R embryo (C, C'), the parietal region (p) of the skull shows no evidence 
for lacZ activity, implying that neural crest cells do not contribute to this region of the skull. In the FGF9/Wnt1-Cre/R26R 
embryo (D, D'), there is also no blue staining in the (enlarged) parietal region. In order to distinguish the staining in the skull (E) 
from the staining in the underlying brain (F, asterisk), the calvarium was removed intact from embryo D and the two parts of 
the head are shown as top views (E, F). Since the dorsal retinal pigmented epithelium in the FGF9 transgenic mice transdiffer-
entiates into the neural retina [30], pigmentation is seen only in the ventral half of the eye (B', arrow). Abbreviations: f, frontal; 
ip, interparietal.BMC Developmental Biology 2006, 6:7 http://www.biomedcentral.com/1471-213X/6/7
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gram of (at least a subset of) the cranial mesenchymal
cells from intramembranous to endochondral ossifica-
tion.
Ectopic expression of the transgene
The skeletal defects in this transgenic line (OVE1070)
occur in mice that are either heterozygous or homozygous
for the FGF9 transgene. It is, therefore, unlikely that the
skull defects in this line of mice are due to disruption of a
gene essential for membranous ossification of the parietal
bones. The transgene expression pattern provides compel-
ling evidence that the skull defects in these mice are due
to ectopic expression of the transgene. In situ hybridiza-
tion analyses show that the transgene is expressed in an
appropriate spatial and temporal pattern to induce the
developmental changes. In addition, the transgene is not
expressed in regions where membranous ossification still
occurs (Fig. 3G). Furthermore, transgene expression pre-
cedes Sox9 expression and condensation of the mesenchy-
mal cells. Also, our results are consistent with the results
of other studies. For example, recent studies of a mouse
model for Apert syndrome, with a single amino acid
change in FGFR2, support the notion that enhanced acti-
vation of FGFR2 can cause some cranial mesenchyme to
convert to a chondrocyte differentiation program [10]. In
addition, FGF9 expression in a chondrocytic cell line is
sufficient to induce expression of Sox9 [42]. Addition of
FGF-2 in vitro to cranial mesenchymal cells from quail
embryos can induce cartilage differentiation at high doses
[17]. Taken together, these results suggest that initiation
of chondrogenesis in the cranial mesenchymal cells in this
line of mice is due to ectopic expression of the FGF9 trans-
gene.
In the OVE1070 family, expression of the FGF9 transgene
is not only ectopic but also transient. Expression in the
cranial mesenchyme was not detectable after E15. This
implies that stimulation by FGF9 is sufficient to induce
(competent) cranial mesoderm to switch to a chondro-
cytic differentiation program, but sustained expression of
FGF9 is not required for the later stages of differentiation.
Therefore, the endochondral ossification program, once
initiated by FGF9, appears to become autonomous.
The reason for the ectopic Fgf9 expression is not clear at
present. It is possible the transgene array has integrated in
the neighborhood of an endogenous enhancer that directs
expression to the cranial mesenchymal cells. Some of the
integrated copies of the transgene still retain the αA-crys-
tallin promoter since the transgene is still expressed in the
lens [30]. The transgene is also expressed in the dorsal
margins of the retinal pigmented epithelium (RPE) and
this expression transforms the RPE into neuroretina [30].
Nature of FGF9 induction
Expression of FGF9 in growth plate chondrocytes using
the Col2a1 promoter results in reduced proliferation and
terminal differentiation of chondrocytes [43]. In addition,
targeted deletion of FGFR3, one of the receptors through
which FGF9 signals, results in mice with overgrowth of
the long bones. These results suggest that a primary role of
FGF signaling in the long bones is to act as a negative reg-
ulator of chondrocyte proliferation. These results are in
contrast to our results that show that ectopic FGF9 expres-
sion in embryonic cranial mesenchymal cells induces
overproliferation followed by endochondral ossification.
How can these disparate observations be reconciled? One
possible explanation is the differential timing of FGF9
expression. The Col2a1 promoter is active in the differen-
tiated chondrocytes, while our transgenic FGF9 is
expressed in undifferentiated cranial mesenchymal cells.
Second, there are differences in the responding tissues.
Chondrocytes in the long bones originate from the lateral
plate mesoderm while the parietal mesenchyme is derived
from cranial mesoderm. Since the stimulated cells have
different developmental origins, there is no reason to
expect that the responses will be identical. For example,
although lens and corneal epithelial cells are related to
each other, both morphologically and developmentally,
they respond differently to FGF stimulation [29,44]. The
reduction in proliferation in the long bones in response to
FGF stimulation may be a unique property of the growth
plate chondrocytes [4]. In contrast, the FGF9-induced pro-
liferation of cranial mesenchymal cells is consistent with
the notion that FGFs, in general, act as mitogens during
normal development.
Endogenous role for FGF9?
Though FGF9 appears to be sufficient to induce chondro-
genesis in the skull, the role of FGF9 during normal devel-
opment of cartilage in the cranium is unclear. Our in situ
hybridizations did not show any detectable expression of
Fgf9 in the calvarial mesenchyme at E11 or E13. Expres-
sion is seen later during embryonic development in the
endocranial portions of the mesenchyme and is downreg-
ulated during postnatal development [16]. This expres-
sion pattern suggests that FGF9 is not important for initial
specification of the cells in the chondrocytic lineage in the
cranium. Consistent with this model, targeted deletion of
FGF9 does not result in any visible skeletal abnormalities
in the skull [24,25]. In contrast, in the transgenic mice, the
ectopic FGF9 plays an instructive role and initiates chon-
drogenesis. FGF9 is known to signal through FGFR2 and
FGFR3 [45]. Signaling by FGF9 in the transgenic heads is
likely to be mediated initially through FGFR2 rather than
FGFR3 as the parietal fate switch in the FGF9 transgenic
mice is not rescued by the loss of FGFR3. After Sox9
expression has been induced and the chondrocytic pro-
gram has been initiated (by E13), expression of the FGF9BMC Developmental Biology 2006, 6:7 http://www.biomedcentral.com/1471-213X/6/7
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transgene is no longer required. In contrast to the normal
chondrocytic differentiation program in long bones,
ectopic chondrogenesis in the cranium proceeds at a
much slower rate. Though the reasons for this are pres-
ently unclear, we speculate that this may be due to the
multi-step nature of the endochondral differentiation
program. Respecification and reprogramming of the pari-
etal environment is required, and this is accomplished in
a less timely fashion than at the normal sites of differenti-
ation.
FGFRs and intramembranous ossification
Our findings are in apparent conflict with some of the cur-
rent models for the roles of FGF receptors in intramem-
branous ossification. Autosomal dominant mutations in
FGFR2 or FGFR3 lead to premature differentiation and
fusion of the skull sutures in humans and these effects are
thought to be the consequence of enhanced receptor activ-
ity [9]. Based upon such a model, our transgenic mice
would be predicted to exhibit an analogous phenotype,
i.e. craniosynostosis. Inappropriate activation of the
receptors in the cranial mesenchyme would be predicted
to lead to premature differentiation. However, our studies
indicate that ligand-mediated activation of FGFR2
induces proliferation of embryonic cranial mesenchymal
cells and subsequent differentiation into cartilage. By
extrapolation then, our results imply that mutations in
the FGFR2 gene in human patients do not result in ligand-
independent constitutive activation of the receptor. This
prediction is supported by the finding that targeted inacti-
vation of FGFR2 in mice causes developmental alterations
in cell types that are not affected by the putative gain-of-
function mutations. An alternative explanation is that
transient stimulation of FGFR2 (as seen in our FGF9 trans-
genic mice) may lead to a qualitatively different cellular
response compared to sustained ligand-independent
stimulation of FGFR2 (as seen in the gain-of-function
mutations in human patients). In either case, our results
show that a single FGF can function as an instructive sig-
nal, inducing a specific cell type to switch from one differ-
entiation program to an autonomous, alternative
differentiation pathway.
Conclusion
Although the mechanistic details of FGF9 stimulation of
the cranial mesenchymal cells remain to be elucidated,
the OVE1070 transgenic mice provide the first demonstra-
tion in vivo that an FGF can switch the differentiation pro-
gram of immature cranial mesoderm. These results also
demonstrate that mesoderm-derived cranial mesenchy-
mal cells are developmentally flexible and can undergo
either intramembranous or endochondral ossification in
response to extracellular signals. These transgenic mice
provide a model system in which to elucidate the molec-
ular connection between stimulation of an FGFR (FGFR2)
and induction of expression of a cell-fate-determining
transcription factor (Sox9).
Methods
Generation of FGF9 transgenic mice
The construction of the FGF9 transgene and the genera-
tion of transgenic mice have been described previously
[29]. The coding region of mouse Fgf9 (a gift from Dr.
David M. Ornitz, Washington University School of Medi-
cine, St. Louis) was inserted between the αA-crystallin pro-
moter [46] and the SV40 small t intron/polyadenylation
sequences of the CPV2 vector [47]. FGF9 transgenic mice
were identified by isolating genomic DNA and screening
by PCR, using primers specific to the SV40 portion of the
transgene: 5'-GTGAAGGAACCTTACTTCTGTGGTG-3'
(SV40A) and 5'-GTCCTTGGGGTCTTCTACCTTTCTC-3'
(SV40B). The PCR cycle conditions were as follows: dena-
turation at 94°C for 30 seconds, annealing at 58°C for 30
seconds and extension at 72°C for 60 seconds, for 35
cycles. A final extension step of 72°C for 10 minutes was
included.
Skeletal preparations
Skeletal preparations were performed as described previ-
ously [48]. Briefly, embryos were first skinned, and evis-
cerated, then fixed in 95% alcohol. After fixation, the
samples were stained with Alcian blue, for 1–2 days. The
samples were then destained in 95% ethanol for eight
hours, and cleared in 2% potassium hydroxide from eight
hours to overnight depending on the size of the specimen.
After clearing, the samples were stained in Alizarin red/
1% potassium hydroxide overnight. The samples were
cleared in 1% potassium hydroxide and 20% glycerol/1%
potassium hydroxide for 2–3 days. Subsequently, the
samples were allowed to harden in 1:1 95% ethanol/glyc-
erol for one day and then transferred to absolute glycerol
for storage and photography.
Histological analyses
For routine histology, embryos were obtained from timed
pregnancies using FVB/N females that were mated to het-
erozygous FGF9 transgenic males. Embryos were deliv-
ered by Caesarean section, fixed in 10% formalin,
dehydrated, embedded in paraffin, sectioned (5 µm) and
stained with hematoxylin and eosin.
Section in situ hybridizations
To analyze the expression of different markers, in situ
hybridizations were performed. Mouse cDNA clones for
Col2a1, Col10a1, Ihh and Sox9 were obtained from Dr.
Benoit DeCrombrugghe (University of Texas, MD Ander-
son Cancer Center, Houston). Mouse cDNA clones for
CbfaI  and  osteocalcin  were obtained from Dr. Gerard
Karsenty (Baylor College of Medicine, Houston). cDNAs
clones for Fgf9, Fgfr2 and Fgfr3 were obtained from Dr.BMC Developmental Biology 2006, 6:7 http://www.biomedcentral.com/1471-213X/6/7
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David Ornitz (Washington University School of Medi-
cine, St. Louis). To analyze expression of the FGF9 trans-
gene, a [35S]-UTP-labeled riboprobe specific to the SV40
sequences of the transgene was made (see Fig. 1). To assay
for endogenous Sox9 expression, a Sox9 antisense probe
was synthesized using a HindIII-digested mouse Sox9
cDNA and T7 RNA polymerase (Promega). For Col2a1,
the antisense probe was synthesized using EcoRI-digested
DNA and T3 RNA polymerase. The antisense probe for
Col10aI was synthesized using a HindIII-digested mouse
Col10a1 cDNA and T3 RNA polymerase. The antisense
probe for Ihh  was synthesized using a BamHI-digested
mouse Ihh cDNA and T7 RNA polymerase. The antisense
probe for Fgf9  was synthesized using a KpnI-digested
mouse Fgf9 cDNA and SP6 RNA polymerase. The anti-
sense probe for CbfaI  was synthesized using an EcoRI-
digested mouse CbfaI cDNA and T7 RNA polymerase. The
antisense probe for osteocalcin  was synthesized using
BamHI-digested mouse osteocalcin cDNA and T3 RNA
polymerase. The antisense probe for Fgfr2 was synthesized
using an EcoRI-digested mouse Fgfr2 cDNA and T7 RNA
polymerase. The antisense probe for Fgfr3 was synthesized
using a HindIII-digested mouse Fgfr3 cDNA and T3 RNA
polymerase. In situ hybridizations on tissue sections were
done using hybridization and washing conditions
described previously [49]. The hybridized slides were
soaked in Kodak NTB-2 emulsion, dried and exposed for
3–5 days at 4°C. Following development and fixation, the
slides were lightly counterstained with hematoxylin.
Proliferation assay
DNA replication was examined by BrdU incorporation as
described previously [50]. Cell proliferation was analyzed
by counting the number of BrdU positive nuclei from
more than 100 cells in a defined area in the parietal region
in three serial sections from four (E11) or six (E13) non-
transgenic and FGF9 transgenic heads. The counts for
BrdU-positive cells in nontransgenic and transgenic mice
were compared using the t-test (p < 0.01).
Whole mount in situ hybridizations
For whole mount in situ hybridizations, tissue samples
were washed thrice in PBS and fixed in 4% paraformalde-
hyde. Hybridizations were performed using digoxygenin-
labeled sense or antisense SV40 riboprobes following
standard procedures [51].
Histochemical detection of β-galactosidase activity
Embryos were obtained from timed pregnancies of R26R
homozygote females mated to OVE1070/Wnt1cre double
transgenic males [36]. X-Gal staining was performed as
described previously [44]. Briefly, heads of E17 embryos
were collected and fixed for 2 hours at 4°C in 0.1 M phos-
phate buffer (pH 7.3) containing 2% paraformaldehyde,
0.2% glutaraldehyde. Following fixation, the tissue sam-
ples were rinsed thrice at room temperature in 0.1 M
phosphate buffer (pH 7.3) containing 0.01% sodium
deoxycholate, 0.02% NP-40, 2 mM MgCl2, then stained in
an X-gal substrate solution (0.01% sodium deoxycholate,
0.02% NP-40, 2 mM MgCl2, 5 mM potassium ferricya-
nide, 5 mM potassium ferrocyanide, 1 mg/ml X-gal in 0.1
M phosphate buffer (pH 7.3)).
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